Lapatinib ditosylate

Trade Name: 
Tykerb
Manufacturer/Distributor: 
GlaxoSmithKline
1-800-387-7374 (Medical Information); www.gsk.ca
Classification: 
Antineoplastic agent
ATC Class: 
L01XE07 Lapatinib
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2009/05/15
Date Marketed in Canada (yyyy/mm/dd): 
2009/05
Presentation: 
Tablet: 250 mg; DIN 02326442
Comments: 
To be used in combination with capecitabine for treatment of patients with advanced or metastatic breast cancer (tumours overexpress HER2). Before starting lapatinib, patients should have already used taxanes, anthracycline and trastuzumab.